R. J. Amato - Concepedia

Author

R. J. Amato

The University of Texas MD Anderson Cancer Center

Also Known As

R Amato, R J Amato, R. AMATO, R. Amato, R. J. Amato, R.J. Amato, RJ Amato

121

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Spanish Oncology Genitourinary Group Moffitt Cancer Center Houston Methodist The University of Texas Health Science Center at Houston

About

R. J. Amato is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	1.2K
2	Health Sciences	6	6	916
3	Immunology	2	2	21
4	Diagnostic Sciences	1	1	85
5	Obstetrics	1	1	27

R. J. Amato

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers GM Mead, SP Stenning, Penny A. Cook, University of Groningen research database (University of Groningen / Centre for Information Technology)	1997	1K
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. C. Logothetis, F. H. Dexeus, Laura Finn, Journal of Clinical Oncology Urological ResearchUrologyGenitourinary CancerMvac-treated PatientsMvac Chemotherapy	1990	616
Chemotherapy for renal cell carcinoma. R. J. Amato PubMed	2000	268
Collecting Duct Carcinoma of the Kidney Meletios Α. Dimopoulos, C. Logothetis, Avi B. Markowitz, British Journal of Urology	1993	139
Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Avishay Sella, Robert G. Kilbourn, R. J. Amato, Journal of Clinical Oncology	1994	120
Escalated Therapy for Refractory Urothelial Tumors: Methotrexate- Vinblastine-Doxorubicin- Cisplatin Plus Unglycosylated Recombinant Human Granulocyte-macrophage Colony-Stimulating Factor Christopher J. Logothetis, F. H. Dexeus, Avishay Sella, JNCI Journal of the National Cancer Institute	1990	114
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) R. J. Amato, A. Misellati, Muhammad Khan, Journal of Clinical Oncology Progressive MrccMetronomic ChemotherapyTumor BiologyPre-clinical PharmacologyNeuro-oncology	2006	106
A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC) R. J. Amato, Patricia Harris, Martin L. Dalton, Journal of Clinical Oncology Therapeutic Drug MonitoringIntra-patient Dose-escalated SorafenibUrologyPhase Ii TrialGenitourinary Cancer	2007	85
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Julie A. Ellerhorst, Shi‐Ming Tu, R. J. Amato, PubMed PharmacotherapyMetronomic ChemotherapyAlternating ScheduleOncologyGenitourinary Cancer	1997	79
Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. Christopher J. Logothetis, L D Finn, Theresa J. Smith, Journal of Clinical Oncology	1995	76

Page 1